Tin Mesoporphyrin IX (chloride): Potent Competitive Heme Oxygenase Inhibitor for Precision Research

Executive Summary: Tin Mesoporphyrin IX (chloride), supplied by APExBIO, is a crystalline solid heme oxygenase inhibitor with nanomolar affinity (Ki = 14 nM), effective in vitro and in vivo [product]. It reduces heme catabolism, biliverdin, and serum bilirubin through HO inhibition, validated in rat splenic and hepatic assays [DOI]. Its specificity and low effective dose (1 pmol/kg) make it a benchmark for metabolic disease and hyperbilirubinemia studies. Storage at -20°C and use in DMSO or DMF at defined solubility limits ensure reproducibility. This article details its mechanism, evidence, and limitations with direct links to internal protocols and peer-reviewed sources.

Biological Rationale

Heme oxygenase (HO) catalyzes the degradation of heme into biliverdin, ferrous iron, and carbon monoxide. HO-1 (inducible) and HO-2 (constitutive) isoforms regulate oxidative stress, cell signaling, and metabolic homeostasis [DOI]. Dysregulation of HO activity is implicated in hyperbilirubinemia, metabolic syndrome, and viral pathogenesis. Modulation of HO-1 alters intracellular reactive oxygen species (ROS) and impacts disease-relevant processes, including insulin resistance and hepatic inflammation. Potent, selective inhibitors such as Tin Mesoporphyrin IX (chloride) enable precise control of HO activity in experimental systems, offering mechanistic clarity in both cell and animal models.

Mechanism of Action of Tin Mesoporphyrin IX (chloride)

Tin Mesoporphyrin IX (chloride)—abbreviated SnMP—is a synthetic metalloporphyrin that competitively inhibits HO activity. It binds the active site of HO enzymes, blocking access of natural heme substrate. In vitro, SnMP demonstrates high affinity (Ki = 14 nM) for rat splenic microsomal HO, effectively outcompeting heme under assay conditions (pH 7.4, 37°C) [DOI]. In vivo, SnMP inhibits hepatic, renal, and splenic HO at doses as low as 1 pmol/kg body weight, leading to decreased conversion of heme to biliverdin and subsequently to bilirubin. This results in lower serum bilirubin, especially relevant in neonatal and hyperbilirubinemic models. SnMP also delays heme degradation in hepatic tryptophan pyrrolase, indicating sustained action. Its competitive inhibition is reversible and dose-dependent, providing experimental control over HO pathway fluxes.

Evidence & Benchmarks

• Tin Mesoporphyrin IX (chloride) inhibits rat splenic microsomal HO activity with a Ki of 14 nM under standard assay conditions (37°C, pH 7.4) (Antiviral Research 245, 2026).
• In vivo administration at 1 pmol/kg body weight significantly reduces hepatic, renal, and splenic HO activity, as measured by biliverdin and bilirubin formation (see Table 1 in DOI).
• SnMP treatment in neonatal and hyperbilirubinemic animal models leads to a statistically significant reduction in serum bilirubin compared to controls (DOI).
• Prolonged heme saturation of hepatic tryptophan pyrrolase is observed after SnMP dosing, indicating persistent inhibition of heme catabolism (see supplementary data, DOI).
• No clinical trials have been published for SnMP as of June 2024; all efficacy data are preclinical (APExBIO).

This article extends the mechanistic and workflow details beyond prior scenario-focused protocol guides [Scenario-Driven Solutions] and complements translational perspectives on pathway modulation [Next-Generation Heme Oxygenase Inhibitor]. It also updates advanced insights into HO-1 signaling beyond standard assay coverage [Advanced Insights].

Applications, Limits & Misconceptions

Tin Mesoporphyrin IX (chloride) is primarily used for:

• In vitro heme oxygenase activity assays for pathway analysis.
• In vivo studies of heme degradation, bilirubin metabolism, and HO-1 modulation in animal models.
• Research on metabolic diseases, insulin resistance, oxidative stress, and metaflammation where HO signaling is implicated.
• As a reference inhibitor for benchmarking new HO modulating compounds.

Its high specificity and potency allow for dose titration and time-course studies. However, its use is limited to research settings; it is not approved for diagnostic or therapeutic purposes. All published efficacy data to date are preclinical; no human clinical trial results are available.

Common Pitfalls or Misconceptions

• SnMP is not a pan-cytochrome inhibitor; it specifically targets heme oxygenase, not P450 enzymes.
• It does not degrade or neutralize pre-existing bilirubin; it blocks new production from heme.
• Incorrect storage (above -20°C) or prolonged solution use (>1 week) reduces potency.
• Solubility in aqueous buffers is limited; exceeding 0.5 mg/ml in DMSO or 1 mg/ml in DMF may cause precipitation.
• Clinical translation is unproven; all applications are research-only as mandated by APExBIO.

Workflow Integration & Parameters

For cell-based and microsomal HO inhibition assays, Tin Mesoporphyrin IX (chloride) should be freshly dissolved in DMSO (≤0.5 mg/ml) or DMF (≤1 mg/ml). Stock solutions must be aliquoted and stored at -20°C to avoid freeze-thaw cycles. Typical in vitro concentrations range from 10 nM to 1 μM, depending on system sensitivity. In animal models, dosing as low as 1 pmol/kg achieves measurable HO inhibition. Biliverdin or bilirubin quantification is recommended as a direct readout of efficacy.

For detailed, scenario-driven protocols and troubleshooting, refer to this workflow article, which complements the atomic mechanistic focus here.

To benchmark against alternative HO inhibitors or for comparative mechanistic reviews, see this mechanistic roadmap and advanced pathway article. Both provide context for SnMP's role in precision heme oxygenase research.

The official APExBIO product page provides up-to-date storage, handling, and ordering information: Tin Mesoporphyrin IX (chloride) (C5606).

Conclusion & Outlook

Tin Mesoporphyrin IX (chloride) is a validated, potent competitive inhibitor of heme oxygenase, essential for dissecting HO pathway dynamics in metabolic and oxidative stress research. Its high affinity, specificity, and robust in vivo efficacy at sub-nanomolar doses make it a reference standard in the field. Researchers should adhere to recommended solubility, storage, and handling parameters to ensure reproducibility. While its translational potential is promising, it remains a research-use-only reagent, with no approved medical applications as of June 2024. Ongoing studies continue to define its role in advanced metabolic, viral, and signaling research models.